



Elite Diagnostic Limited

Unaudited Interim Financial Statements

First Quarter ended September 30, 2019

Contents

	Page
Directors' report	
Financial Statements	
Unaudited statement of financial position	3
Unaudited statement of profit or loss and other comprehensive income	4
Unaudited statement of changes in equity	5
Unaudited statement of cash flows	6
Notes to the unaudited interim financial statements	7



The Board of Directors of Elite Diagnostic Limited is pleased to present the company's 1st Quarter Unaudited Financial Statements ending September 30, 2019.


Revenues for the quarter were \$118 Million compared to \$85.4 Million on the previous year. Net profit amounted to \$16.7 Million compared to \$1.8 Million the previous year. Total Assets were \$680.5 Million compared to \$588.1 Million compared to the previous year. Total Liabilities were \$212.6 Million compared to \$186.7 Million the previous year.

Revenues were \$96,761,440 during the 2nd quarter compared to \$71,852,668 for the same period last year. The increase in revenue for the 2nd quarter is due to MRI scans and increase in Intervention procedures. For the six months ending December 31, 2018, revenues were \$182,243,884 compared with \$141,667,567 for the same period a year ago.


The company opened their third location in late September 2019. This branch is located in Drax Hall, St Ann. Along with full imaging services, the facility also includes doctor offices. The company is very optimistic with the potential of this new facility with its premium location, close proximity to the St. Ann Bay Hospital and the need for a medical center in the area.

The company continues to execute their plan of providing exceptional patient care, excellent customer service, investing in State-of-the-Art equipment and expanding their services.

The company wishes to thank all our valued customers, the dedicated staff and the referring physicians for their continued support.



Director



Director


November 13, 2019


Unaudited statement of financial position

September 30, 2019

	Unaudited September 2019 \$	Unaudited September 2018 \$	Audited June 2019 \$
Assets			
Non-current assets			
Property, plant and equipment	572,764,964	480,445,337	561,751,984
	572,764,964	480,445,337	561,751,984
Current assets			
Receivables	28,396,197	17,369,767	25,238,546
Prepayments	4,339,408	162,494	652,798
Cash and cash equivalents	75,042,474	90,100,502	76,422,723
	107,778,079	107,632,763	102,314,067
Total assets	680,543,043	588,078,100	664,066,051
Equity			
Share capital	348,898,459	348,898,459	348,898,459
Retained earnings	119,002,480	52,431,486	102,309,387
Total equity	467,900,939	401,329,945	451,207,846
Liabilities			
Non-current liabilities			
Long-term loans	195,533,261	158,061,550	195,666,638
	195,533,261	158,061,550	195,666,638
Current liabilities			
Payables and accruals	15,908,837	1,649,605	15,591,567
Current portion of long-term loans	1,200,006	27,037,000	1,600,000
	17,108,843	28,686,605	17,191,567
Total liabilities	212,642,104	186,748,155	212,858,205
Total equity and liabilities	680,543,043	588,078,100	664,066,051

Approved for issue by the Directors on November 13, 2019 and signed on its behalf by:


Warren Chung


Neil Fong

The notes on the accompanying pages form an integral part of these financial statements.

Unaudited statement of profit or loss and other comprehensive income First Quarter ended September 30, 2019

	Unaudited Three months ended September 30, 2019 \$	Unaudited Three months ended September 30, 2018 \$	Audited year ended June 30, 2019 \$
Income	117,999,130	85,437,038	404,866,849
Direct costs	(39,824,765)	(27,564,858)	(126,256,676)
Gross profit	78,174,365	57,872,180	278,610,173
Other income	576	45,406	222,401
Administrative expenses	(40,127,646)	(37,833,452)	(147,982,961)
Depreciation	(17,430,319)	(13,976,452)	(55,825,533)
Operating profit	20,616,976	6,107,682	75,024,080
Finance costs	(4,948,579)	(4,279,415)	(20,077,997)
Gain/(loss) on foreign exchange	1,024,696	9,872	(3,123,482)
Net profit and comprehensive income for the period/year	16,693,093	1,838,139	51,822,601
Basic and diluted earnings per share	0.04	0.005	0.15

The notes on the accompanying pages form an integral part of these financial statements.

Unaudited statement of changes in equity First Quarter ended September 30, 2019

	Share capital \$	Accumulated surplus \$	Total \$
Balance at June 30, 2018 - Audited	348,898,459	50,593,347	399,491,806
Profit for the three months ended September 30, 2018	-	1,838,139	1,838,139
Balance at September 30, 2018	348,898,459	52,431,486	401,329,945
Balance at June 30, 2018 - Audited	348,898,459	50,593,347	399,491,806
Adjustment from adoption of IFRS 9	-	(106,561)	(106,561)
Adjusted balance at July 1, 2018	348,898,459	50,486,786	399,385,245
Profit for the year being total comprehensive income for the year	-	51,822,601	51,822,601
Adjusted balance at June 30, 2019 - Audited	348,898,459	102,309,387	451,207,846
Balance at June 30, 2019 - Audited	348,898,459	102,309,387	451,207,846
Profit for the period ended September 30, 2019 being total comprehensive income for the year - unaudited	-	16,693,093	16,693,093
Balance at September 30, 2019 - Unaudited	348,898,459	119,002,480	467,900,939

The notes on the accompanying pages form an integral part of these financial statements.

Unaudited statement of cash flows

First Quarter ended September 30, 2019

	Unaudited Three months ended September 30, 2019 \$	Unaudited Three months ended September 30, 2018 \$	Audited Year ended June 30, 2019 \$
Cash flows from operating activities:			
Profit before tax	16,693,093	1,838,139	51,822,601
Adjustments for:			
Interest expense	4,948,579	4,279,415	55,825,533
Depreciation	17,430,319	13,976,452	20,077,997
Adoption of IFRS 9	-	-	(106,561)
	39,071,991	20,094,006	127,619,570
Increase in receivables	(3,157,651)	(6,713,052)	(14,581,831)
(Increase)/decrease in prepayments	(3,686,610)	4,406,916	3,916,611
Increase/(decrease) in payables and accruals	317,270	(2,987,723)	10,954,239
Cash provided by operations	32,545,000	14,800,147	127,908,589
Interest paid	(4,948,579)	(4,279,415)	(20,077,997)
Net cash provided by operations	27,596,421	10,520,732	107,830,592
Cash flow from investing activities			
Purchase of property, plant and equipment	(28,443,299)	(39,876,137)	(163,031,864)
Net cash used in investing activities	(28,443,299)	(39,876,137)	(163,031,864)
Cash flow from financing activities			
Proceeds from loans	-	-	195,000,000
Repayment of loans	(533,371)	(2,563,776)	(185,395,688)
Net cash (used in)/provided by financing activities	(533,371)	(2,563,776)	9,604,312
Net decrease in cash and cash equivalents	(1,380,249)	(31,919,181)	(45,596,960)
Cash and cash equivalents at beginning of year	76,422,723	122,019,683	122,019,683
Cash and cash equivalents at end of year	75,042,474	90,100,502	76,422,723

The notes on the accompanying pages form an integral part of these financial statements.

Notes to the unaudited interim financial statements

September 30, 2019

1. General information and nature of operations

Elite Diagnostic Limited was incorporated under the laws of Jamaica on February 12, 2012 and is domiciled in Jamaica. The company commenced operations in August 2013. The company's principal place of business is located at 1b Holborn Road, Kingston 5.

The company provides diagnostic imaging services.

2. Statement of compliance

a Basis of preparation

These financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) IAS 34, Interim Financial Reporting.

The interim financial report is to be read in conjunction with the audited financial statements for the year ended June 30, 2019. The significant accounting policies adopted are consistent with those of the audited financial statements for the year ended June 30, 2019.

b Critical judgements and sources of estimation uncertainty

The preparation of these financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements. These estimates are based on historical experience and management's best knowledge of current events and actions. Actual results may differ from these estimates and assumptions.

Elite Diagnostic Limited

Notes to the unaudited interim financial statements
First Quarter ended September 30, 2019

3. Share capital

	Unaudited Three months ended September 30, 2019 \$	Audited June 30, 2019 \$
Authorised ordinary units of no par value	Unlimited	Unlimited
Issued ordinary units of no par value	353,400,000	353,400,000
Stated capital: Issued and fully paid ordinary stocks of no par value	348,898,459	348,898,459

Earnings per shares

	Unaudited Three months ended September 30, 2019 \$	Unaudited Three months ended September 30, 2018 \$
Profit attributable to shareholders	16,693,093	1,838,139
Weighted average number of shares	353,400,000	353,400,000
Earnings per shares	0.04	0.005

Elite Diagnostic Limited

Notes to the unaudited interim financial statements
Year ended September 30, 2019

List of Directors, Connected Parties and Senior Managers Shareholdings As at September 30, 2019

Directors and connected parties

Directors

Names	Position	Shares Held	Percentages %
Steven Gooden	Chairman	242,230	0.0685
Warren Chung	Executive Director	757,626	0.2144
Neil Fong	Executive Director	140,000	0.0396
Andre Ho Lung	Non-Executive Director	161,494	0.0457
Kevin Donaldson	Non-Executive Director	140,000	0.0396
Paula Kerr-Jarrett	Non-Executive Director	NIL	NIL
Quentin Hugh Sam	Non-Executive Director	824,573	0.2333
Peter D. Chin	Non-Executive Director	140,000	0.0396
William Mahfood	Non-Executive Director	172,025	0.0487
		2,577,948	0.7294

Connected parties

Connected to

Excel Investments	Warren Chung and Neil Fong	145,140,264	41.0697
Barnett Limited	Paula Kerr-Jarrett	15,515,994	4.3905
Combined Key Member Holdings		163,234,206	46.1896

Senior Managers

Names	Position	Shares Held	Percentages %
Warren Chung	Chief Executive Officer	757,626	0.2144
Neil Fong	Senior Manager	140,000	0.0396
Marjorie Miller	Manager	-	-
		897,626	0.2540

Top 10 Shareholders

Names	Shares Held	Percentages %
1. Excel Investments (See connected party note below)	145,140,264	41.0697
2. NCB Capital Markets Limited	66,028,392	18.6838
3. JCSD Trustee Services Limited - Sigma Optima	31,438,024	8.8959
4. West Indies Radiology Outsourcing Ltd.	17,670,000	5.0000
5. Barnett Limited	15,515,994	4.3905
6. Kevin Keaton Palmer	3,908,151	1.1059
7. Lizette Mowatt	3,703,632	1.0480
8. VM Wealth Equity Fund	3,390,939	0.9595
9. SJIML A/C 3119	3,188,169	0.9021
10. QWI Investments Limited	2,949,877	0.8347
Total units owned by top 10 Shareholders	292,933,442	82.8901
Total Issued Capital	353,400,000	

Excel Investments is a connected party to Warren Chung and Neil Fong, Executive Directors.

